natgillin/translations-raw huggingface dataset:
Absorption: Efter oral administration af valsartan alene opnås valsartans maksimale plasmakoncentration efter 2-4 timer.
Absorption: Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2–4 hours.
Absorption: Hos hiv-inficerede voksne patienter giver Invirase i kombination med ritonavir i doser på 1.000/100 mg 2 gange daglig en systemisk tilgængelighed af saquinavir over en 24-timers periode svarende til eller højere end opnåede værdier med saquinavir bløde kapsler 1.200 mg 3 gange daglig (se tabel 8).
Absorption : In HIV-infected adult patients, Invirase in combination with ritonavir at doses of 1000/100 mg twice daily provides saquinavir systemic exposures over a 24-hour period similar to or greater than those achieved with saquinavir soft capsules 1200 mg tid (see Table 8).
Absorption: Maravirocs absorption er variabel med multiple toppe.
Absorption: the absorption of maraviroc is variable with multiple peaks.
Absorption: Memantin har en absolut biotilgængelighed på ca.
Absorption: Memantine has an absolute bioavailability of approximately 100%.
Absorption: Nevirapin absorberes hurtigt (>90 %) efter oral administration hos raske forsøgspersoner og hos voksne hiv-1 smittede.
Absorption: Nevirapine is readily absorbed (> 90 %) after oral administration in healthy volunteers and in adults with HIV-1 infection.
Absorption: Ranolazins gennemsnitlige absolutte biotilgængelighed efter oral administration af ranolazin-tabletter med øjeblikkelig frigivelse var 35–50 % med store interindividuelle forskelle.
Absorption: The mean absolute bioavailability of ranolazine after oral administration of immediate- release ranolazine tablets ranged from 35−50%, with large inter-individual variability.
Absorption: Rasagilin absorberes hurtigt og når peak plasmakoncentration (Cmax) efter ca.
Absorption: Rasagiline is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately
Absorptionen af dolutegravir reduceres af visse syreneutraliserende lægemidler (se tabel 1).
The absorption of dolutegravir is reduced by certain anti-acid agents (see Table 1).
absorptionen af efavirenz.
expected to affect efavirenz
Absorptionen af nelfinavir kan være nedsat i situationer, hvor det gastriske pH er øget uden hensynstagen til årsagen.
absorption of nelfinavir may be reduced in situations where the gastric pH is increased
Absorptionen af tipranavir er højere fra oral opløsning end når den samme dosis gives, som kapsler.
Compared to the capsules, tipranavir exposure is higher when administering the same dose as oral solution.
Absorptionen af tipranavir er højere, fra oral opløsning end når den samme dosis gives, som kapsler.
Compared to the capsules, tipranavir exposure is higher when administering the same dose as oral solution.
Absorptionen af tipranavir er mindre fra kapsler end når den samme dosis gives, som oral opløsning.
Compared to the oral solution, tipranavir exposure is lower when administering the same dose as capsules.
Absorptionen begrænses ikke af stoffets passage af tarmbarrieren, men er primært bestemt af en omfattende first pass-effekt.
Absorption is not limited by penetration of the drug across the intestinal barrier but is predominantly influenced by an extensive first pass effect.
Absorptionen er fuldstændig og vurderet på areal under kurve- (AUC) værdierne.
Absorption is complete based on mean area under the curve (AUC) values.
Absorptionen er variabel og den orale gennemsnitlige biotilgængelighed af tacrolimus ligger mellem 20 % - 25 % (individuelt hos voksne patienter 6 % - 43 %).
Absorption is variable and the mean oral bioavailability of tacrolimus is in the range of 20%-25% (individual range in adult patients 6%-43%).
Absorptionen sker lidt hurtigere ved subkutan injektion i abdominalæggen end ved brug af andre injektionssteder (se pkt.
Subcutaneous injection in the abdominal wall ensures a slightly faster absorption than other injection sites (see section 5.2).
Absorptionshastighed og -grad for Onduarp er ækvivalent med telmisartans og amlodipins biotilgængelighed, når de gives som individuelle tabletter.
The rate and extent of absorption of Onduarp are equivalent to the bioavailability of telmisartan and amlodipine when administered as individual tablets.
Absorptionshastighed og -omfang for metformin fra Icandra 50 mg/1000 mg blev reduceret ved indgivelse med mad, som er afspejlet af en reduktion i Cmax på 26 %, AUC på 7 % og forsinket Tmax (2,0 til 4,0 t).
The rate and extent of absorption of metformin from Icandra 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax (2.0 to 4.0 h).
Absorptionshastighed og –grad af sirolimus øges signifikant af ciclosporin (CsA).
The rate and extent of sirolimus absorption was significantly increased by ciclosporin A (CsA).
Absorptionshastigheden af pregabalin nedsættes ved samtidig indtagelse af føde, hvilket nedsætter Cmax med ca.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately
Absorptionshastigheden var noget langsommere for patienter med type 2-diabetes, hvilket resulterede i en lavere Cmax (352240 pmol/l) og senere tmax (60 (interkvartilt interval: 50-90) minutter).
The absorption rate was somewhat slower in type 2 diabetic patients, resulting in a lower Cmax (352240 pmol/l) and later tmax (60 (interquartile range: 50–90) minutes).
Absorptionsraten og –udbredelsen påvirkes ikke af fødeindtagelse, hvorfor Ketek tabletter kan gives uden hensyn til fødeindtagelse.
The rate and extent of absorption is unaffected by food intake, and thus Ketek tablets can be given without regard to food.
abstinens symptomer.
opiate withdrawal syndrome.
Abstinens-
4.4)12
Abstinens-
Discontinuation
Abstinens-
Dyskinesia6
Abstinens-
eizures were
Abstinens- symptomer hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see 4.6)
Abstinens- symptomer7,1
Tardive dyskinesia11
Abstinens- symptomer7,12
Dysarthria
Abstinens- symptomer7,12
oculogyration)11
Abstinens- syndrom hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see 4.6)
abstinens- syndrom hos nyfødte (Se pkt.
drug withdrawal syndrome neonatal (see section 4.6)
Abstinens- syndromc, indurationc
Hyperprolactinaemia
Abstinens- syndromc, indurationc
temperature decreasedc, drug withdrawal syndromec, indurationc
Abstinens- syndromc, indurationc,
congestion, dysphonia
Abstinenss yndrom hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssy mptomer712
Dysarthria
Abstinenssympto m, neonatal (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssymptom er7, 12
Discontinuation Symptoms 7, 12
Abstinenssymptom er7,12
Dyskinesia6
Abstinenssymptom er712
Discontinuation Symptoms 712
Abstinenssymptomer
Withdrawal symptoms
abstinenssymptomer hos nyfødte ved indgivelse under graviditet,
withdrawal symptoms in newborn babies in case of exposure during pregnancy,
abstinenssymptomer.
signs of opiate withdrawal.
abstinenssymptomer.
symptoms.
abstinenssymptomerne.
Osteonecrosis
abstinenssymptomerne.
withdrawal symptoms.
abstinenssymptomerne.
ymptoms.
Abstinenssyn drom hos nyfødte (se pkt.
Drug withdrawal
Abstinenssyn drom hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssynd rom hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssyndro m
Drug withdrawal syndrome
Abstinenssyndro m hos det nyfødte barn (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssyndro m hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssyndrom
Drug Withdrawal Syndrome
Abstinenssyndrom *
Withdrawal syndrome
Abstinenssyndrom hos nyfødte (se
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssyndrom hos nyfødte (se pkt.
Drug withdraw al syndrome neonatal (see section 4.6)
Abstinenssyndrom hos nyfødte (se pkt.
Drug withdrawal syndrome neonatal (see section 4.6)
Abstinenssyndrom hos nyfødte (se pkt.
drug withdrawal syndrome neonatal (see section 4.6)c
abstinenssyndrom hos nyfødte (se pkt.
drug withdrawal syndrome neonatal (see section 4.6)e
Abstinenssyndrom hos nyfødte (se pkt.
In the long-term
Abstinenssyndrom hos nyfødte (se pkt.
neonatal (see section 4.6)
Abstinenssyndrom hos nyfødte (se pkt.
pulmonary congestion
Abstinenssyndrom hos nyfødte (se pkt.
Refer to ‘Hyperprolactinaemia’ below.
AC
0.96)
AC-052-355 var et multicenter, randomiseret dobbeltblindt parallelgruppestudie af bosentan sammenlignet med placebo hos 33 patienter med alvorlig pulmonal arteriel hypertension, som var i samtidig behandling med epoprostenol.
AC-052-355 was a multi-centre, randomised, double- blind, parallel-group study of bosentan versus placebo in 33 patients with severe pulmonary arterial hypertension who were receiving concomitant epoprostenol therapy.
AC-052-355 var et multicenter, randomiseret dobbeltblindt parallelgruppestudie af bosentan sammenlignet med placebo hos 33 patienter med alvorlig pulmonal arteriel hypertension, som var i samtidig behandling med epoprostenol.
AC-052-355 was a multi-centre, randomised, double-blind, parallel-group study of bosentan versus placebo in 33 patients with severe pulmonary arterial hypertension who were receiving concomitant epoprostenol therapy.
Acarbose
Common
acarbose (et lægemiddel, som anvendes til behandling af type 2-sukkersyge). alli anbefales ikke til personer, som tager acarbose.
acarbose, (an anti-diabetic drug used to treat type 2 diabetes mellitus). alli is not recommended for people taking acarbose.
acarbose (et lægemiddel, som anvendes til behandling af type 2-sukkersyge). alli anbefales ikke til pesoner, som tager acarbose.
acarbose, (an anti-diabetic drug used to treat type 2 diabetes mellitus). alli is not recommended for people taking acarbose.
Accelereret CML (n=137)*
Accelerated phase (n=137)
Accelereret eliminationsprocedure: Colestyramin og aktivt kul
Accelerated Elimination Procedure: Cholestyramine and activated charcoal
Accelereret fase
Accelerated Phase
Accelereret fase defineres som tilstedeværelse af én eller flere af følgende: blaster 15%, men <30% i blod eller knoglemarv, blaster plus promyelocytter 30% i blod eller knoglemarv (hvilket giver <30% blaster), perifere blodbasofiltal 20%, trombocyttal <100 x 109/l uafhængigt af behandlingen.
Accelerated phase is defined by the presence of any of the following: blasts  15% but < 30% in blood or bone marrow, blasts plus promyelocytes  30% in blood or bone marrow (providing < 30% blasts), peripheral blood basophils  20%, platelets < 100 x 109/l unrelated to therapy.
ACCENT I (uge-2 responderende)
ACCENT I (Week-2 responders)
ACCENT I (uge-2 responderende)
ACCENT II (Week-14 responders)
ACCENT I (uge-2 responderende)
at both Week 8 and Week 30)
ACCENT II (uge-14 responderende)
ACCENT II (Week-14 responders)
ACCENT II (uge-14 responderende)
Effects on response rate, data from ACCENT II (week-14 responders)
accharinnatrium, natriumchlorid,
accharin sodium, sodium chloride,
accharosepalmitat naturligt og kunstigt smagsstof.
ucrose palmitate natural and artificial flavour
Accofil , som indeholder r-metHuG-CSF (filgrastim) forårsager signifikante stigninger af neutrofiltallet i perifert blod inden for 24 timer med mindre stigninger af monocyttallet.
Accofil containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Accofil 30 ME/0,5 ml
Accofil 30 MU/0.5 ml
Accofil 30 ME/0,5 ml (0,6 mg/ml) injektions- og infusionsvæske, opløsning i en fyldt injektionssprøjte filgrastim
Accofil 30 MU/0.5 ml (0.6 mg/ml) solution for injection or infusion in pre-filled syringe filgrastim
Accofil 30 ME/0,5 ml injektions- og infusionsvæske, opløsning filgrastim
Accofil 30 MU/0.5 ml solution for injection/infusion filgrastim
Accofil 30 ME/0,5 ml injektions- og infusionsvæske, opløsning, i en fyldt injektionssprøjte
Accofil 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Accofil 48 ME/0,5 ml
Accofil 48 MU/0.5 ml
Accofil 48 ME/0,5 ml (0,96 mg/ml) injektions- og infusionsvæske, opløsning i en fyldt injektionssprøjte filgrastim
Accofil 48 MU/0.5 ml (0.96 mg/ml) solution for injection or infusion in pre-filled syringe filgrastim
Accofil 48 ME/0,5 ml injektions- og infusionsvæske, opløsning filgrastim
Accofil 48 MU/0.5 ml solution for injection/infusion filgrastim
Accofil 48 ME/0,5 ml injektions- og infusionsvæske, opløsning, i en fyldt injektionssprøjte
Accofil 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Accofil anvendes ved flere forskellige tilstande som:
Accofil is useful in several different conditions which are:
Accofil bør IKKE anvendes, hvis det har været udsat for frostgrader i mere end 24 timer eller har været nedfrosset mere end én gang.
If exposure has been greater than 24 hours or frozen more than once then Accofil should NOT be used.
Accofil bør ikke fortyndes i natriumchloridinjektionsvæske.
Accofil should not be diluted with sodium chloride solution.
Accofil er et biosimilært lægemiddel.
Accofil is a biosimilar medicinal product.
Accofil findes i pakninger, der indeholder 1, 3, 5, 7 eller 10 fyldte injektionssprøjter med fortil monteret kanylebeskytter i individuel blisterpakning eller uden kanylebeskytter/blisterpakning samt spritserviet(ter).
Accofil is available in packs containing 1, 3, 5, 7 and 10 pre-filled syringes, with prefixed needle safety guard in individual blister pack or without needle safety guard / blister and alcohol swabs.
Accofil findes i pakninger, der indeholder 1, 3, 5, 7 eller 10 fyldte injektionssprøjter med fortil monteret kanylebeskytter i individuelle blisterpakninger eller uden kanylebeskytter/blisterpakning samt spritserviet(ter).
Accofil is available in packs containing 1, 3, 5, 7 and 10 pre-filled syringes, with prefixed needle safety guard in individual blister pack or without needle safety guard / blister and alcohol swabs.
Accofil indeholder ingen konserveringsmidler.
Accofil contains no preservative.
Accofil indeholder sorbitol og natrium
Important information about some of the ingredients of Accofil
Accofil må ikke fortyndes med natriumchloridinfusionsvæske.
Accofil must not be diluted with saline solutions.
Accofil s sikkerhed og virkning er den samme hos voksne og børn, der får cytotoksisk kemoterapi.
The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.
Accofil, der indeholder det aktive stof filgrastim, er et “biosimilært lægemiddel”.
Accofil, which contains the active substance filgrastim, is a ‘biosimilar medicine’.
Accord Healthcare Limited Sage House
Accord Healthcare Limited Sage House, 319 Pinner Road, North Harrow,
Accord Healthcare Limited Sage House, 319 Pinner Road,
Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow,
Accord Healthcare Limited Sage house, 319 Pinner Road,
Accord Healthcare Limited, Sage house, 319 Pinner road, North Harrow,
ACCORD HEALTHCARE LIMITED – Sage House – 319 Pinner Road – Harrow – Middlesex HA1 4HF – ENGLAND
ACCORD HEALTHCARE LIMITED - Sage House - 319 Pinner Road – Harrow – Middlesex HA1 4HF - United Kingdom
ACCORD HEALTHCARE LIMITED – Sage House – 319 Pinner Road – Harrow – Middlesex HA1 4HF – ENGLAND
ACCORD HEALTHCARE LIMITED - Sage House - 319 Pinner Road – Harrow – Middlesex HA1 4HF – UK
ACE (Angiotensin Converting Enzyme)-hæmmere (til behandling af visse hjertelidelser eller forhøjet blodtryk)
Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
ACE (angiotensin konverteringsenzym)-hæmmere (til behandling af visse hjertelidelser eller forhøjet blodtryk)
Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
ACE-hæmmere (angiotensin-konverterings-enzym-hæmmere) (til behandling af visse hjertelidelser eller for højt blodtryk)
Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
ACE-hæmmere (angiotensin-konverterings-enzym-hæmmere) (til behandling af visse hjertelidelser eller forhøjet blodtryk)
Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)
ACE-hæmmere (anvendes til at behandle højt blodtryk) såsom enalapril eller captopril
ACE inhibitors (used to treat high blood pressure), such as enalapril or captopril
ACE-hæmmere (mod hjertelidelser)
ACE-inhibitors (used to treat heart conditions)
ACE-hæmmere (mod hjertelidelser)
ACE-inhibitors (used to treat heart conditions).
ACE-hæmmere (mod hjertelidelser).
ACE-inhibitors (used to treat heart conditions).
ACE-hæmmere eller aliskiren (se også information under overskrifterne ”Tag ikke Copalia HCT” og ”Advarsler og forsigtighedsregler”).
ACE inhibitors or aliskiren (see also information under the headings “Do not take Copalia HCT” and “Warnings and precautions”).
ACE-hæmmere eller aliskiren (se også information under overskrifterne ”Tag ikke Copalia HCT” og ”Advarsler og forsigtighedsregler”).
ACE inhibitors or aliskiren (see also information under the headings “Do not take Copalia HCT” and “Warnings and precautions”)..
ACE-hæmmere eller aliskiren (se også information under overskrifterne ”Tag ikke Copalia HCT” og ”Advarsler og forsigtighedsregler”).
ACE inhibitors or aliskiren –(see also information under the headings “Do not take Copalia HCT” and “Warnings and precautions”).
ACE-hæmmere eller aliskiren (se også information under overskrifterne ”Tag ikke Dafiro HCT” og ”Advarsler og forsigtighedsregler”).
ACE inhibitors or aliskiren (see also information under the headings “Do not take Dafiro HCT” and “Warnings and precautions”).
ACE-hæmmere eller aliskiren (se også information under overskrifterne ”Tag ikke Dafiro HCT” og ”Advarsler og forsigtighedsregler”).
ACE inhibitors or aliskiren –(see also information under the headings “Do not take Dafiro HCT” and “Warnings and precautions”) .
ACE-hæmmere eller aliskiren - se også information under overskrifterne ”Tag ikke Twynsta” og ”Advarsler og forsigtighedsregler”.
ACE-inhibitors or aliskiren (see also information under the headings “Do not take Twynsta” and “Warnings and precautions”).
ACE-hæmmere eller aliskiren - se også information under overskrifterne”Tag ikke Twynsta” og ”Advarsler og forsigtighedsregler”.
ACE-inhibitors or aliskiren (see also information under the headings “Do not take Twynsta” and “Warnings and precautions”).
ACE-hæmmere eller Angiotensin II-receptorantagonister (medicin mod højt blodtryk og hjertesvigt)
ACE inhibitors or Angiotensin II receptor antagonists (used for high blood pressure and heart failure)
ACE-hæmmere fluconazol
ACE inhibitors, fluconazole.
ACE-hæmmere fluoxetin allopurinol sympatolytika
ACE inhibitors fluoxetine allopurinol sympatholytics
ACE-hæmmere og angiotensin II-receptorantagonister bør derfor ikke anvendes samtidigt hos patien- ter med diabetisk nefropati.
ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.
ACE-hæmmere og angiotensin II-receptorantagonister bør ikke anvendes samtidigt hos patienter med diabetisk nefropati.
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy
ACE-hæmmere og angiotensin II-receptorantagonister bør ikke anvendes samtidigt hos patienter med diabetisk nefropati..
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.
ACE-hæmmere).
ACE inhibitors.
ACE-hæmmere, angiotensin II-receptorantagonister, renin-hæmmere.
ACE inhibitors, angiotensin II receptor antagonists, renin inhibitors.
ACE-hæmmere, angiotensin-II-hæmmere, betablokkere og diuretika – anvendes mod forhøjet blodtryk og hjertelidelser
ACE inhibitors, Angiotensin-II inhibitors, beta blockers and diuretics – used for high blood pressure and heart conditions
ACE-hæmmere, kaliumbesparende diuretika, kaliumtilskud, saltsubstitutter der indeholder kalium, ciclosporin eller andre lægemidler, f.eks. heparin-natrium)
ACE inhibitors, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, cyclosporine or other medicinal products such as heparin sodium)
ACE-hæmmere, kaliumbesparende diuretika, kaliumtilskud, saltsubstitutter der indeholder kalium, ciclosporin eller andre lægemidler, f.eks. heparin-natrium)
ACE inhibitors, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, cyclosporine or other medicinal products such as heparin sodium).
ACE-hæmmere, sympatolytika, disopyramid, pentoxifyllin, coumarin-derivater som f.eks. warfarin (til behandling af hjerte- eller blodproblemer)
ACE inhibitors, sympatholytics, disopyramide, pentoxifylline, coumarin derivatives such as warfarin (to treat heart or blood problems)
ACE-hæmmere.
ACE inhibitors.
acetat
(0.37, 1.03)
acetazolamid, et lægemiddel der anvendes til at behandle glaukom (forhøjet tryk i øjet) eller epilepsi eller til at øge urinflow.
acetazolamide, a medicine used to treat glaucoma (increased ocular pressure) or epilepsy or to increase urine flow,
Acetylator- fænotype
Acetylator Phenotype
Acetylcholin er nødvendig for at overføre elektriske impulser fra nerverne til musklerne, så musklerne trækker sig sammen.
Acetylcholine is needed to transfer electrical impulses from the nerves to the muscles in order for the muscles to contract.
Acetylcholin frigives fra nerveenderne under en "depolariseringsperiode".
Acetylcholine is released from the nerve endings during a period of ‘depolarisation’.
Acetylerings status
Acetylation status
acetylglutamat-syntetase- (NAGS) og CITRIN (citrullinæmi type 2-) defekt
acetylglutamate synthase (NAGS) and CITRIN (citrullinaemia type 2) deficiency
Acetylsalicylsyre (ASA), heparin, nitroglycerin
Acetylsalicylic acid (ASA), Heparin, Nitrogycerin
Acetylsalicylsyre (ASA): ASA ændrede ikke på, at clopidogrel hæmmer den trombocytaggregation, som ADP inducerer,, men clopidogrel forstærkede virkningen af ASA den trombocytaggregation som kollagen inducerer.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
acetylsalicylsyre (også kaldet aspirin) eller acetylsalicylsyre plus clopidogrel eller ticlopidin.
acetylsalicylic acid (also known as aspirin) or acetylsalicylic acid plus clopidogrel or ticlopidine.
acetylsalicylsyre - mod feber og smerter - i doser over 325 mg pr. dag
acetylsalicylic acid – to relieve fever and pain - at doses above 325 mg per day
acetylsalicylsyre eller acetylsalicylsyre plus clopidogrel eller ticlopidin.
acetylsalicylic acid (also known as aspirin) or acetylsalicylic acid plus clopidogrel or ticlopidine.
acetylsalicylsyre eller anden medicin, der dæmper betændelse
Acetylsalcylic acid or other anti-inflammatory medicines
Acetylsalicylsyre eller andre antiinflammatoriske lægemidler
Acetylsalicylic acid (aspirin) or other anti-inflammatory medicines
Acetylsalicylsyre hæmmer trombocytaggregation ved irreversibel hæmning af prostaglandincyklo- oxygenase og hæmmer derved dannelsen af tromboxan A2, en inducer af trombocytaggregation og vasokonstriktion.
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Acetylsalicylsyre og andre nonsteroide antiinflammatoriske lægemidler (NSAIDer) (inkl. ibuprofen, diclofenacnatrium og naproxen) kan virke irriterende på maven og tarmen.
Acetylsalicylic acid and other non-steroidal anti-inflammatory medicines (NSAIDs) (including ibuprofen, diclofenac sodium and naproxen) may irritate the stomach and intestine.
acetylsalicylsyre*
acetylsalicylic acid
acetylsalicylsyre,
acetyl salicylic acid,
acetylsalicylsyre,
acetylsalicylic acid,